

ISO 14155:2011-02 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice

Contents		Page
Foreword		v
1	Scope	1
2	Normative references	1
3	Terms and definitions	2
4	Ethical considerations	7
4.1	General	7
4.2	Improper influence or inducement	8
4.3	Compensation and additional health care	8
4.4	Responsibilities	8
4.5	Communication with the ethics committee (EC)	8
4.5.1	General	8
4.5.2	Initial EC submission	8
4.5.3	Information to be obtained from the EC	9
4.5.4	Continuing communication with the EC	9
4.5.5	Continuing information to be obtained from the EC	9
4.6	Vulnerable populations	9
4.7	Informed consent	10
4.7.1	General	10
4.7.2	Process of obtaining informed consent	10
4.7.3	Special circumstances for informed consent	10
4.7.4	Information to be provided to the subject	11
4.7.5	Informed consent signature	13
4.7.6	New information	13
5	Clinical investigation planning	14
5.1	General	14
5.2	Risk evaluation	14
5.3	Justification for the design of the clinical investigation	14
5.4	Clinical investigation plan (CIP)	14
5.5	Investigator's brochure (IB)	15
5.6	Case report forms (CRFs)	15
5.7	Monitoring plan	15
5.8	Investigation site selection	15
5.9	Agreement(s)	15
5.10	Labelling	15
5.11	Data monitoring committee (DMC)	16
6	Clinical investigation conduct	16
6.1	General	16
6.2	Investigation site initiation	16
6.3	Investigation site monitoring	16
6.4	Adverse events and device deficiencies	16
6.4.1	Adverse events	16
6.4.2	Device deficiencies	16
6.5	Clinical investigation documents and documentation	17
6.5.1	Amendments	17
6.5.2	Subject identification log	17
6.5.3	Source documents	17

6.6	Additional members of the investigation site team	17
6.7	Subject privacy and confidentiality of data	17
6.8	Document and data control	18
6.8.1	Traceability of documents and data	18
6.8.2	Recording of data	18
6.8.3	Electronic clinical data systems	18
6.9	Investigational device accountability	19
6.10	Accounting for subjects	19
6.11	Auditing	19
7	Suspension, termination and close-out of the clinical investigation	20
7.1	Suspension or premature termination of the clinical investigation	20
7.1.1	Procedure for suspension or premature termination	20
7.1.2	Procedure for resuming the clinical investigation after temporary suspension	21
7.2	Routine close-out	21
7.3	Clinical investigation report	21
7.4	Document retention	22
8	Responsibilities of the sponsor	22
8.1	Clinical quality assurance and quality control	22
8.2	Clinical investigation planning and conduct	23
8.2.1	Selection of clinical personnel	23
8.2.2	Preparation of documents and materials	23
8.2.3	Conduct of clinical investigation	24
8.2.4	Monitoring	24
8.2.5	Safety evaluation and reporting	27
8.2.6	Clinical investigation close-out	27
8.3	Outsourcing of duties and functions	28
8.4	Communication with regulatory authorities	28
9	Responsibilities of the principal investigator	28
9.1	General	28
9.2	Qualification of the principal investigator	28
9.3	Qualification of investigation site	29
9.4	Communication with the EC	29
9.5	Informed consent process	29
9.6	Compliance with the CIP	29
9.7	Medical care of subjects	30
9.8	Safety reporting	31
	Annex A (normative) Clinical investigation plan (CIP)	32
	Annex B (normative) Investigator's brochure (IB)	39
	Annex C (informative) Case report forms (CRFs)	41
	Annex D (informative) Clinical investigation report	43
	Annex E (informative) Essential clinical investigation documents	48
	Annex F (informative) Adverse event categorization	55
	Bibliography	58